T cell vaccination (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01448252 (ClinicalTrials.gov) | May 2002 | 5/10/2011 | T Cell Vaccination in Patients With Progressive Multiple Sclerosis | Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis | Multiple Sclerosis | Biological: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides);Biological: T cell vaccination | Hadassah Medical Organization | NULL | Completed | 18 Years | 60 Years | Both | 30 | Phase 1;Phase 2 | Israel |
| 2 | NCT00228228 (ClinicalTrials.gov) | May 2002 | 26/9/2005 | TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis | T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis | Multiple Sclerosis | Biological: T cell vaccination | Sheba Medical Center | NULL | Recruiting | 15 Years | 50 Years | Both | 80 | Phase 3 | Israel |